AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30837595 — intervention group
Group type: COMPARATOR
Intervention: Triple P (behavior management)
Number of subjects: 60
Study 30171370 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex
Number of subjects: 186
Study 30171370 — intervention group
Group type: COMPARATOR
Intervention: CinnoVex
Number of subjects: 186
Study 27006189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 7576
Study 27006189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 7576
Study 25269900 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative group (before OLT)
Number of subjects: 20
Study 25269900 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative group (after OLT)
Number of subjects: 20
Study 22701531 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the web portal
Number of subjects: 96
Study 22701531 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study 21134048 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (20 U)
Number of subjects: 247
Study 21134048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 17933438 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet enriched in eicosapentanoic acid (EPA), gamma-linolenic acid (GLA), vitamins A, C, and E
Number of subjects: 100
Study 17933438 — intervention group
Group type: COMPARATOR
Intervention: Control diet similar in macronutrient composition
Number of subjects: 100
Study 16277797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Number of subjects: 104
Study 16277797 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 104
Study 11840418 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (taxane and platinum compound)
Number of subjects: 0
Study 11840418 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line treatments (not specified)
Number of subjects: 0
Study 11840418 — intervention group
Group type: EXPERIMENTAL
Intervention: New combination regimens (gemcitabine, topotecan, encapsulated doxorubicin with carboplatin plus paclitaxel)
Number of subjects: 0
Study 11840418 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological approaches (drugs interfering with angiogenesis, matrix metalloproteinases, signal transduction pathways)
Number of subjects: 0
Study 11840418 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with a biologic agent for six cycles followed by chronic maintenance biologic therapy
Number of subjects: 0
Study 9933701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative chemotherapy with MMC (10 mg/patient) and UFT 300 mg/day (P1 group)
Number of subjects: 78
Study 9933701 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 600 mg/day (P2 group)
Number of subjects: 78
Study 9933701 — intervention group
Group type: COMPARATOR
Intervention: UFT 300 mg/day (P0 group)
Number of subjects: 78
Study 9933701 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 300 mg/day (H1 group)
Number of subjects: 78
Study 9933701 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 600 mg/day (H2 group)
Number of subjects: 78
Study 7767538 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluticasone nasal spray (200 micrograms daily)
Number of subjects: 0
Study 7767538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2306061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of ranitidine (50 mg every 8 hours and 75 mg every 12 hours)
Number of subjects: 12
Study 2306061 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of ranitidine (75, 150, and 300 mg every 24 hours)
Number of subjects: 12
Study 2306061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6455095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin hydrochloride
Number of subjects: 358
Study 6455095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin phosphate
Number of subjects: 358
Study 6455095 — intervention group
Group type: COMPARATOR
Intervention: Hydroalcoholic vehicle (placebo)
Number of subjects: 358
Study 6455095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin hydrochloride and 1% clindamycin phosphate
Number of subjects: 358
Study 30676479 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Tract Dilation classification system
Number of subjects: 243
Study 30676479 — intervention group
Group type: COMPARATOR
Intervention: Society for Fetal Urology scale
Number of subjects: 243
Study 27616745 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐DAY sodium nitrate supplementation (1097 mg sodium nitrate providing 800 mg nitrate per day)
Number of subjects: 17
Study 27616745 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐DAY sodium nitrate supplementation (1097 mg sodium nitrate providing 800 mg nitrate per day)
Number of subjects: 17
Study 27616745 — intervention group
Group type: COMPARATOR
Intervention: PLA (5 days placebo and 1 day sodium nitrate supplementation)
Number of subjects: 17
Study 26805529 — intervention group
Group type: EXPERIMENTAL
Intervention: APRV group
Number of subjects: 26
Study 26805529 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 26805529 — intervention group
Group type: COMPARATOR
Intervention: APRV group and Control group
Number of subjects: 26
Study 23837918 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOCAF (25 g carbohydrate + 100 mg caffeine)
Number of subjects: 12
Study 23837918 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (25 g carbohydrate)
Number of subjects: 12
Study 23837918 — intervention group
Group type: COMPARATOR
Intervention: PL (non-caloric placebo)
Number of subjects: 12
Study 21880336 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta-1a, 44 mcg sc three times weekly (tiw)
Number of subjects: 180
Study 21880336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 19606472 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5-10 mg/day)
Number of subjects: 123
Study 19606472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 17348082 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage allocation rule for binary response
Number of subjects: 0
Study 14998944 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET) 1.5 to 2.55 g/day
Number of subjects: 42
Study 14998944 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 42
Study 11591562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity residential exercise training program
Number of subjects: 24
Study 11591562 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 9498432 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 96
Study 8059918 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 days of sodium stibogluconate (Pentostam) at 20 mg/kg/day
Number of subjects: 40
Study 8059918 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 days of sodium stibogluconate (Pentostam) at 20 mg/kg/day
Number of subjects: 40
Study 3189721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (after reinstitution of treatment)
Number of subjects: 20
Study 3189721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (withdrawal)
Number of subjects: 20
Study 31663640 — intervention group
Group type: EXPERIMENTAL
Intervention: CT (Conditioning Training)
Number of subjects: 49
Study 31663640 — intervention group
Group type: EXPERIMENTAL
Intervention: CT with feedback
Number of subjects: 49
Study 31663640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31663640 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 49
Study 29710164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily) + Aspirin (100 mg once daily)
Number of subjects: 500
Study 29710164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily)
Number of subjects: 500
Study 29710164 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg once daily)
Number of subjects: 500
Study 28755042 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus home visiting (n=99)
Number of subjects: 203
Study 28755042 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic care (n=104)
Number of subjects: 203
Study 25271201 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (3-month yoga course of group classes and home practice)
Number of subjects: 61
Study 25271201 — intervention group
Group type: COMPARATOR
Intervention: Normal medical care (Control)
Number of subjects: 61
Study 24053631 — intervention group
Group type: EXPERIMENTAL
Intervention: Family meetings intervention
Number of subjects: 192
Study 24053631 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 192
Study 21812923 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) 1.5 mg/day
Number of subjects: 2004
Study 21812923 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) 3.0 mg/day
Number of subjects: 2004
Study 21812923 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA) with standard dose cyclosporine (SD‐CsA)
Number of subjects: 2004
Study 19302885 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation using genetic information about obesity
Number of subjects: 411
Study 19302885 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized consultation without genetic information
Number of subjects: 411
Study 19302885 — intervention group
Group type: COMPARATOR
Intervention: Control group without any intervention
Number of subjects: 411
Study 16495245 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 25 mg/day
Number of subjects: 0
Study 16495245 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 50 mg/day
Number of subjects: 0
Study 16495245 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 100 mg/day
Number of subjects: 0
Study 16495245 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 200 mg/day
Number of subjects: 0
Study 16495245 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 400 mg/day
Number of subjects: 0
Study 16495245 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 800 mg/day
Number of subjects: 0
Study 16495245 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine (all doses)
Number of subjects: 0
Study 12605972 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (64 Gy in 32 fractions within 6.5 weeks)
Number of subjects: 120
Study 12605972 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated radiotherapy (55 Gy in 20 fractions within 4 weeks)
Number of subjects: 120
Study 12605972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment schedules (Conventional and Hypofractionated)
Number of subjects: 120
Study 11092290 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE 901)
Number of subjects: 619
Study 11092290 — intervention group
Group type: COMPARATOR
Intervention: NPH human insulin
Number of subjects: 619
Study 9314855 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) administration (150 micrograms intra-arterial bolus, with or without a 10 mg GTN patch for 24 hours)
Number of subjects: 83
Study 9314855 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo administration
Number of subjects: 83
Study 8444719 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptamine (5-HT)
Number of subjects: 8
Study 8444719 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP)
Number of subjects: 8
Study 8444719 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8
Study 3097726 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg nicotine during stress
Number of subjects: 12
Study 3097726 — intervention group
Group type: COMPARATOR
Intervention: Stress alone (placebo)
Number of subjects: 12
Study 3097726 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg nicotine alone
Number of subjects: 12
Study 3097726 — intervention group
Group type: COMPARATOR
Intervention: Rest + placebo (control)
Number of subjects: 12
Study 3097726 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress + nicotine
Number of subjects: 12
Study 3097726 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest + nicotine
Number of subjects: 12
Study 31563909 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonized Cognitive Assessment Protocol (HCAP) cognitive test battery, including in-person interviews lasting approximately 1 hour with the respondent and 20 minutes with an informant.
Number of subjects: 3496
Study 30242809 — intervention group
Group type: COMPARATOR
Intervention: NPSR1 (rs324981) T/T genotype
Number of subjects: 600
Study 30242809 — intervention group
Group type: COMPARATOR
Intervention: NPSR1 (rs324981) AT genotype
Number of subjects: 600
Study 30242809 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall coping style
Number of subjects: 600
Study 26810768 — intervention group
Group type: EXPERIMENTAL
Intervention: AD+CAD
Number of subjects: 257
Study 26810768 — intervention group
Group type: COMPARATOR
Intervention: AD-only
Number of subjects: 257
Study 26810768 — intervention group
Group type: EXPERIMENTAL
Intervention: AD+CAD (among APOE ε4 allele carriers)
Number of subjects: 257
Study 25551436 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression (BATD)
Number of subjects: 281
Study 25551436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 281
Study 25551436 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 281
Study 22775412 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin lactone
Number of subjects: 52
Study 22775412 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin acid
Number of subjects: 52
Study 20104219 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low-dose peginterferon alpha-2a (90 microg/week)
Number of subjects: 129
Study 20104219 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 129
Study 18779512 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP infusion (1.5 microg/min)
Number of subjects: 19
Study 18779512 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy participants)
Number of subjects: 19
Study 16137507 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (250 ml daily, Cabernet Sauvignon)
Number of subjects: 20
Study 16137507 — intervention group
Group type: COMPARATOR
Intervention: Control (abstinence from alcoholic beverages)
Number of subjects: 20
Study 12366475 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (bicycle ergometer, >6 mM blood lactate)
Number of subjects: 20
Study 12366475 — intervention group
Group type: COMPARATOR
Intervention: Control condition (minimal activity, no lactate elevation)
Number of subjects: 20
Study 12366475 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 20
Study 12366475 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study 10480671 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (oral dl-fenfluramine)
Number of subjects: 35
Study 10480671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 8722429 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone system for monitoring and counseling
Number of subjects: 267
Study 8722429 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 267
Study 1760767 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium oxalate
Number of subjects: 34
Study 1760767 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach calcium (intrinsic label)
Number of subjects: 34
Study 1760767 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach calcium (extrinsic label)
Number of subjects: 34
Study 1760767 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk calcium (alone)
Number of subjects: 34
Study 1760767 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk calcium (co-ingested with spinach)
Number of subjects: 34
Study 1760767 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach calcium (co-ingested with milk)
Number of subjects: 34
Study 1760767 — intervention group
Group type: COMPARATOR
Intervention: Labeled oxalate (co-fed with labeled milk)
Number of subjects: 34
Study 6127219 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 14
Study 6127219 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg bid
Number of subjects: 14
Study 6127219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30209126 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4850
Study 30209126 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4850
Study 30209126 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban and Warfarin
Number of subjects: 4850
Study 28558252 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise at 40%-50% oxygen uptake reserve (LI)
Number of subjects: 0
Study 28558252 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise at 70%-80% oxygen uptake reserve (HI)
Number of subjects: 0
Study 28558252 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise plus EPOC re-feeding (HI+EERM)
Number of subjects: 0
Study 28558252 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 0
Study 25928161 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity module
Number of subjects: 1828
Study 25928161 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking module
Number of subjects: 1828
Study 25928161 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit module
Number of subjects: 1828
Study 25928161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable module
Number of subjects: 1828
Study 25928161 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol module
Number of subjects: 1828
Study 25928161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use module
Number of subjects: 1828
Study 23702006 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM) at haemoglobin level (Hb) of 7 g/dl
Number of subjects: 1000
Study 23702006 — intervention group
Group type: COMPARATOR
Intervention: Transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM) at haemoglobin level (Hb) of 9 g/dl
Number of subjects: 1000
Study 23702006 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM)
Number of subjects: 1000
Study 21837955 — intervention group
Group type: COMPARATOR
Intervention: Plasmakinetic transurethral resection of the prostate (PKRP)
Number of subjects: 81
Study 21837955 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral detaching resection (TUDRP)
Number of subjects: 81
Study 19627013 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine (60 mL: lumbar-plexus 36 mL, sciatic nerve 24 mL)
Number of subjects: 60
Study 19627013 — intervention group
Group type: COMPARATOR
Intervention: 0.4% ropivacaine (45 mL: lumbar-plexus 27 mL, sciatic nerve 18 mL)
Number of subjects: 60
Study 19627013 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine
Number of subjects: 60
Study 19627013 — intervention group
Group type: COMPARATOR
Intervention: 0.4% ropivacaine
Number of subjects: 60
Study 17556348 — intervention group
Group type: COMPARATOR
Intervention: Single-vessel disease
Number of subjects: 2082
Study 17556348 — intervention group
Group type: COMPARATOR
Intervention: Double-vessel disease
Number of subjects: 2082
Study 17556348 — intervention group
Group type: COMPARATOR
Intervention: Triple-vessel disease
Number of subjects: 2082
Study 15167303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-dose (40 mg isoflavones + 500 mg calcium)
Number of subjects: 203
Study 15167303 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (80 mg isoflavones + 500 mg calcium)
Number of subjects: 203
Study 15167303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg isoflavones + 500 mg calcium)
Number of subjects: 203
Study 11874640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT)
Number of subjects: 46
Study 11874640 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support/counseling group therapy (PSC)
Number of subjects: 46
Study 11874640 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment with no formal psychosocial intervention (Control)
Number of subjects: 46
Study 9805118 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples obtained from peripheral venous catheters
Number of subjects: 53
Study 9805118 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-gauge catheters
Number of subjects: 53
Study 9805118 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge catheters
Number of subjects: 53
Study 9805118 — intervention group
Group type: COMPARATOR
Intervention: Venipuncture (control group)
Number of subjects: 53
Study 9805118 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral catheter samples
Number of subjects: 53
Study 9805118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptable interval for potassium measurements
Number of subjects: 53
Study 9805118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptable interval for hemoglobin measurements
Number of subjects: 53
Study 8690170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (2.9 mmol/l) for 2 hours during hypo week
Number of subjects: 8
Study 8690170 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia (5 mmol/l) for 2 hours during control week
Number of subjects: 8
Study 2543203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet (25% of calories from fat, P:S of 1.0, 200 mg cholesterol/d, 40 g dietary fiber/d)
Number of subjects: 17
Study 2543203 — intervention group
Group type: COMPARATOR
Intervention: Typical Western diet (40% of total calories from fat, 400 mg cholesterol/d, 12 g dietary fiber/d, P:S of 0.5)
Number of subjects: 17